An analysis of the economic impact of smoking cessation in Europe

BMC Public Health

Paul S Jarvis¹  M Fasihul Alam¹  David Cohen¹ 

[1] Health Economics and Policy Research Unit, Faculty of Health, Sport and Science, University of Glamorgan, Pontypridd, Mid Glamorgan CF37 1DL, UK

关键词: Policy;    Cost;    Modelling;    Smoking;   

Others  :  1162291
DOI  :  10.1186/1471-2458-13-390

 received in 2012-05-04, accepted in 2013-04-23,  发布年份 2013

【 摘 要 】

Background

There is much evidence that smoking cessation interventions are both clinically and cost effective but these results relate only to the specific study populations involved in the studies. The present study aimed to compare and contrast results obtained when the effects of smoking cessation are modelled for several different European countries.

Methods

Local investigators collected data relating to several smoking related diseases. Costs and disease rates were then modelled up to 2030 for reductions in smoking of 3%, 15% and 30% using an epidemiological modelling tool, PREVENT.

Results

Models could not be constructed for some countries due to lack of data while for others substantial amounts of data had to be imputed. In all cases, disease rates fall when smoking cessation occurs. Overall costs initially fall before eventually rising as lives are saved and the population ages, leading to negative savings in some cases by the end of the modelled period. The speed and magnitude with which these effects occur are diverse for different countries.

Conclusions

Health and economic results for different countries vary significantly for the same reductions in smoking. This suggests that it may be inappropriate to assume that evidence from one country will produce similar health and economic effects if the same levels of smoking cessation were achieved in another country which has evident messages for health policy. Problems with obtaining data also highlight the difficulties associated with modelling such scenarios and underline the need for relevant data to be routinely collected in all countries.

【 授权许可】

   
2013 Cohen et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Evidence Based Medicine Working Group: Evidence based medicine: a new approach to teaching the practice of medicine. J Am Med Assoc 1992, 268:242-245.
• [2]National Institute for Clinical Excellence: Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence; 2004.
• [3]Song F, Raftery J, Aveyard P, Hyde C, Barton P, Woolacott N: Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Medical Decision Making 2002, 22(Supplement):S26-S37.
• [4]Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP: Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005, 8(3):178-190.
• [5]Godfrey C, Parrott S, Coleman T, Pound E: The cost-effectiveness of the English smoking treatment services: evidence from practice. Addiction 2005, 100(Suppl 2):70-83.
• [6]Stapleton J: Cost effectiveness of NHS smoking cessation services. [http://www.ash.org.uk/files/documents/ASH_427.pdf webcite] Accessed May 2, 2012
• [7]Gunning-Schepers L: The health benefits of prevention: a simulation approach. Health Policy 1989, 12(1–2):1-255.
• [8]National Institute for Health and Clinical Excellence: Cost-Effectiveness of Interventions for Smoking Cessation. [http://www.nice.org.uk/nicemedia/pdf/WorkplaceInterventionsPromoteSmokingCessationEconomicReport1.pdf webcite] Accessed May 2, 2012
• [9]Wolstenholme J, Whynes D: The hospital cost of treating lung cancer in the United Kingdom. Br J Cancer 1999, 80:215-218.
• [10]Britton M: The burden of COPD in the UK: results from the confronting COPD survey. Respir Med 2003, 97(Sup C):S71-S79.
• [11]Luengo-Fernandez R, Leal J, Gray A, Petersen S, Rayner M: Cost of Cardiovascular disease in the United Kingdom. Heart 2006, 92:1384-1389.
• [12]Select Committee on Health: Minutes of Evidence. House of Commons. London: The Stationary Office; 2000.
• [13]Wilson D, Adams R, Appleton S, Ruffin R: Difficulties identifying and targeting COPD and population-attributable risk of smoking for COPD. Chest 2005, 128:2035-2042.
• [14]Shinton R, Beevers G: Meta-analysis of relation between cigarette smoking and stroke. Br Med J 1989, 298:789-794.
• [15]World Health Organisation. [http://www.who.int/healthinfo/global_burden_disease/tools_software/en/index.html webcite] Accessed May 2, 2012
• [16]Cohen D, Barton G: The costs to society of smoking cessation. Thorax 1998, 53(S2):S38-S42.
• [17]Bertera RL: The effects of behavioural risks on absenteeism and health care costs in the workplace. J Occup Med 1991, 33:119-124.
• [18]Townsend J: Cost effectiveness and mass media programmes of smoking control. In Smoking control: strategies and evaluation in community and mass media programmes. Edited by Crofton J, Wood M. London: Health Education Council, & Belfast: The Ulster Cancer Foundation, & Edinburgh: Scottish Health Education Group; 1986.
• [19]Parrott S, Godfrey C, Raw M: Cost of employee smoking in the workplace in Scotland. Tob Control 2000, 9:187-192.
• [20]Nelson H: The Economic Consequences of Smoking in Northern Ireland. Belfast: Ulster Cancer Foundation; 1986.